US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File
-
Venezuela's Machado vows to make Nobel Peace Prize ceremony
-
Kidnapping fears strain family bonds in Nigeria
-
'Chosen' Mbappe on way to making Real Madrid history like Ronaldo: Alonso
-
Russian strikes on Ukraine trigger heating, water cuts
-
Mediators Qatar, Egypt call for next steps in Gaza truce
-
Olympic favourite Malinin pulls off stunning GP Final win
-
Venezuela's Machado to receive peace prize in Oslo: Nobel Institute
-
Russell tops practice times to outpace title-chasing trio
-
India bowl out South Africa for 270 after De Kock ton
-
England staring down the barrel under Gabba lights as Australia dominate
-
Egyptian actor faces challenge in iconic role of singer Umm Kulthum
-
Chock and Bates win Grand Prix Final ice dance
-
Starvation fears as flood toll passes 900 in Indonesia
-
Four civilians, soldier killed in Afghan-Pakistan border clash
-
Milan-Cortina chief admits venue time pinch as Olympic torch relay begins
-
England make quick start after Australia take big lead at Gabba
-
Finally! India break toss jinx as Rahul gets lucky
-
Will EU give ground on 2035 combustion-engine ban?
-
England nemesis Starc stretches Australia lead in Gabba Ashes Test
-
Banana skin 'double whammy' derails McIlroy at Australian Open
-
Epic Greaves double ton earns West Indies draw in first NZ Test
-
Thunder roll to 14th straight NBA win, Celtics beat depleted Lakers
-
Myanmar citizens head to early polls in Bangkok
-
Starvation fears as more heavy rain threaten flood-ruined Indonesia
-
Sri Lanka unveils cyclone aid plan as rains persist
-
Avatar 3 aims to become end-of-year blockbuster
-
Contenders plot path to 2026 World Cup glory after Trump steals show at draw
-
Greaves leads dramatic West Indies run chase in NZ Test nail-biter
-
World record-holders Walsh, Smith grab wins at US Open
-
Ukraine, US to meet for third day, agree 'real progress' depends on Russia
-
Double wicket strike as New Zealand eye victory over West Indies
-
Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease
-
Shinoda Dental Named Official Distributor of VHF Milling Machines, Strengthening Its Position in Digital Dentistry
-
Califf Surveying Becomes Leading Supplier of Leica Total Stations in Asia
-
New Memoir In Pursuit of Glory Exposes the High-Stakes Journey to from Laborer to Executive Leadership in a Male-Dominated Industry
-
Peace medal and YMCA: Trump steals the show at World Cup draw
-
NBA legend Jordan in court as NASCAR anti-trust case begins
-
How coaches reacted to 2026 World Cup draw
-
Glasgow down Sale as Stomers win at Bayonne in Champions Cup
-
Trump takes aim at Europe in new security strategy
-
Witness in South Africa justice-system crimes probe shot dead
-
Tuchel urges England not to get carried away plotting route to World Cup glory
-
Russian ambassador slams EU frozen assets plan for Ukraine
-
2026 World Cup draw is kind to favorites as Trump takes limelight
-
WHO chief upbeat on missing piece of pandemic treaty
-
US vaccine panel upends hepatitis B advice in latest Trump-era shift
-
Ancelotti says Brazil have 'difficult' World Cup group with Morocco
-
Kriecmayr wins weather-disrupted Beaver Creek super-G
-
Ghostwriters, polo shirts, and the fall of a landmark pesticide study
-
Mixed day for global stocks as market digest huge Netflix deal
NYSE - LSE
| RBGPF | 0% | 78.35 | $ | |
| JRI | 0.29% | 13.79 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| SCS | -0.56% | 16.14 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| BP | -3.91% | 35.83 | $ |
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
R.Lee--AT
